FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092297625> ?p ?o ?g. }

• W3092297625 endingPage "248" @default.
• W3092297625 startingPage "226" @default.
• W3092297625 abstract "Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To provide additional clinical evidence in regulatory submissions for a modified-release (MR) once-daily (QD) tofacitinib formulation, we compared real-world adherence and effectiveness between patients initiating the MR QD formulation and patients initiating an immediate-release (IR) twice-daily (BID) formulation. Two noninterventional cohort studies were conducted. First, adherence and two effectiveness proxies were compared between patients with RA who newly initiated tofacitinib MR 11 mg QD or IR 5 mg BID in the IBM® MarketScan® Commercial and Medicare Supplemental US insurance claims databases (March 2016–October 2018). Second, using data collected in the Corrona US RA Registry (February 2016–August 2019), two Clinical Disease Activity Index (CDAI)-based measures of effectiveness were compared between tofacitinib MR 11 mg QD and IR 5 mg BID, and against noninferiority criteria derived from placebo-controlled clinical trials of the tofacitinib IR formulation. Multiple sensitivity analyses of the registry data were conducted to reassure regulators of consistent results across different assumptions. In each study, approximately two-thirds of patients initiated the MR formulation. In the claims database study, improved adherence and at least comparable effectiveness were observed with tofacitinib MR vs IR over 12 months, particularly in patients without prior advanced therapy. In the registry study, the noninferiority of tofacitinib MR vs IR was demonstrated for both CDAI outcomes at ~6 months; this finding was robust across multiple sensitivity analyses. These results demonstrate the value of real-world evidence from complementary data sources in understanding the impact of medication adherence with a QD formulation in clinical practice. These analyses were suitable for regulatory consideration as an important component of evidence for the comparability of tofacitinib MR 11 mg QD vs IR 5 mg BID in patients with RA. Claims database study: ClinicalTrials.gov identifier NCT04018001, retrospectively registered July 12, 2019. Corrona US RA Registry study: ClinicalTrials.gov identifier NCT04267380, retrospectively registered February 12, 2020." @default.
• W3092297625 created "2020-10-15" @default.
• W3092297625 creator A5004596365 @default.
• W3092297625 creator A5006742120 @default.
• W3092297625 creator A5009475149 @default.
• W3092297625 creator A5010819140 @default.
• W3092297625 creator A5015604000 @default.
• W3092297625 creator A5030754645 @default.
• W3092297625 creator A5030768494 @default.
• W3092297625 creator A5032039152 @default.
• W3092297625 creator A5032298796 @default.
• W3092297625 creator A5040352377 @default.
• W3092297625 creator A5057538503 @default.
• W3092297625 creator A5060125727 @default.
• W3092297625 creator A5064025296 @default.
• W3092297625 creator A5064863811 @default.
• W3092297625 creator A5066450152 @default.
• W3092297625 creator A5077099389 @default.
• W3092297625 date "2020-10-09" @default.
• W3092297625 modified "2023-10-06" @default.
• W3092297625 title "Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis" @default.
• W3092297625 cites W2061326496 @default.
• W3092297625 cites W2091721419 @default.
• W3092297625 cites W2109479417 @default.
• W3092297625 cites W2114656311 @default.
• W3092297625 cites W2116139481 @default.
• W3092297625 cites W2129168200 @default.
• W3092297625 cites W2131168761 @default.
• W3092297625 cites W2138780114 @default.
• W3092297625 cites W2157399320 @default.
• W3092297625 cites W2201326611 @default.
• W3092297625 cites W2235318197 @default.
• W3092297625 cites W2558871347 @default.
• W3092297625 cites W2562546113 @default.
• W3092297625 cites W2594020302 @default.
• W3092297625 cites W2791072512 @default.
• W3092297625 cites W2804360725 @default.
• W3092297625 cites W2886374740 @default.
• W3092297625 cites W2888686038 @default.
• W3092297625 cites W2905522333 @default.
• W3092297625 cites W2963333516 @default.
• W3092297625 cites W2968610608 @default.
• W3092297625 cites W2992915944 @default.
• W3092297625 cites W3083846810 @default.
• W3092297625 cites W3175417087 @default.
• W3092297625 cites W4211111012 @default.
• W3092297625 cites W4231972505 @default.
• W3092297625 doi "https://doi.org/10.1007/s12325-020-01501-z" @default.
• W3092297625 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7854470" @default.
• W3092297625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33034006" @default.
• W3092297625 hasPublicationYear "2020" @default.
• W3092297625 type Work @default.
• W3092297625 sameAs 3092297625 @default.
• W3092297625 citedByCount "6" @default.
• W3092297625 countsByYear W30922976252021 @default.
• W3092297625 countsByYear W30922976252022 @default.
• W3092297625 countsByYear W30922976252023 @default.
• W3092297625 crossrefType "journal-article" @default.
• W3092297625 hasAuthorship W3092297625A5004596365 @default.
• W3092297625 hasAuthorship W3092297625A5006742120 @default.
• W3092297625 hasAuthorship W3092297625A5009475149 @default.
• W3092297625 hasAuthorship W3092297625A5010819140 @default.
• W3092297625 hasAuthorship W3092297625A5015604000 @default.
• W3092297625 hasAuthorship W3092297625A5030754645 @default.
• W3092297625 hasAuthorship W3092297625A5030768494 @default.
• W3092297625 hasAuthorship W3092297625A5032039152 @default.
• W3092297625 hasAuthorship W3092297625A5032298796 @default.
• W3092297625 hasAuthorship W3092297625A5040352377 @default.
• W3092297625 hasAuthorship W3092297625A5057538503 @default.
• W3092297625 hasAuthorship W3092297625A5060125727 @default.
• W3092297625 hasAuthorship W3092297625A5064025296 @default.
• W3092297625 hasAuthorship W3092297625A5064863811 @default.
• W3092297625 hasAuthorship W3092297625A5066450152 @default.
• W3092297625 hasAuthorship W3092297625A5077099389 @default.
• W3092297625 hasBestOaLocation W30922976251 @default.
• W3092297625 hasConcept C126322002 @default.
• W3092297625 hasConcept C142724271 @default.
• W3092297625 hasConcept C168563851 @default.
• W3092297625 hasConcept C204787440 @default.
• W3092297625 hasConcept C27081682 @default.
• W3092297625 hasConcept C2776233030 @default.
• W3092297625 hasConcept C2777575956 @default.
• W3092297625 hasConcept C2778886723 @default.
• W3092297625 hasConcept C535046627 @default.
• W3092297625 hasConcept C71924100 @default.
• W3092297625 hasConceptScore W3092297625C126322002 @default.
• W3092297625 hasConceptScore W3092297625C142724271 @default.
• W3092297625 hasConceptScore W3092297625C168563851 @default.
• W3092297625 hasConceptScore W3092297625C204787440 @default.
• W3092297625 hasConceptScore W3092297625C27081682 @default.
• W3092297625 hasConceptScore W3092297625C2776233030 @default.
• W3092297625 hasConceptScore W3092297625C2777575956 @default.
• W3092297625 hasConceptScore W3092297625C2778886723 @default.
• W3092297625 hasConceptScore W3092297625C535046627 @default.
• W3092297625 hasConceptScore W3092297625C71924100 @default.
• W3092297625 hasIssue "1" @default.
• W3092297625 hasLocation W30922976251 @default.
• W3092297625 hasLocation W30922976252 @default.

• next